Engineering an Autonucleolytic Mammalian Suspension Host Cell Line to Reduce DNA Impurity Levels in Serum-Free Lentiviral Process Streams-Reference-Cited by-同舟云学术

Engineering an Autonucleolytic Mammalian Suspension Host Cell Line to Reduce DNA Impurity Levels in Serum-Free Lentiviral Process Streams

Published:2024-01-24 Issue: Volume: Page:
ISSN:2161-5063
Container-title:ACS Synthetic Biology
language:en
Short-container-title:ACS Synth. Biol.

Author:

Howe Geoffrey¹,Wasmuth Matthew¹,Emanuelle Pamela¹,Massaro Giulia²,Rahim Ahad A.²,Ali Sadfer¹,Rivera Milena¹,Ward John¹,Keshavarz-Moore Eli¹,Mason Chris¹,Nesbeth Darren N.¹^ORCID

Affiliation:

1. Department of Biochemical Engineering, University College London, Bernard Katz Building, London WC1E 6BT, United Kingdom

2. UCL School of Pharmacy, University College London, London WC1N 1AX, U.K.

Funder

EPSRC

Publisher

American Chemical Society (ACS)

Subject

Biochemistry, Genetics and Molecular Biology (miscellaneous),Biomedical Engineering,General Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acssynbio.3c00682

Reference27 articles.

1. July 24, 2020 Approval Letter - TECARTUS. U.S. Food and Drug Administration, July 24, 2020. https://www.fda.gov/media/140415/download (accessed 2022-12-21).

2. August 30, 2017 Approval Letter - KYMRIAH. U.S. Food and Drug Administration, August 30, 2017. https://www.fda.gov/media/106989/download (accessed 2022-12-21).

3. October 18, 2017 Approval Letter - YESCARTA. U.S. Food and Drug Administration, October 18, 2017. https://www.fda.gov/media/108458/download (accessed 2022-12-21).

4. August 17, 2022 Approval Letter - ZYNTEGLO. U.S. Food and Drug Administration, August 17, 2022. https://www.fda.gov/media/160994/download (accessed 2022-12-21)

5. September 16, 2022 Approval Letter - SKYSONA. U.S. Food and Drug Administration, September 16, 2022. https://www.fda.gov/media/161665/download (accessed 2022-12-21).